Compares treatment outcomes of doublet versus triplet therapy in high-volume metastatic prostate cancer, indicating impactful findings.
Introduction: Data for direct comparison of the outcomes for ADT+androgen signaling pathway-inhibitors (ARPI) vs. ADT+ARPI+docetaxel is scant, especially in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) according to CHAARTED-classification and regarding [for full text, please go to the a.m. URL]
No takes yet. Share an insight, caveat, or question.
Wenzel et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: